12/01/21 6:00 AMOTC : BNOEF, BNOEF.OB U.S. FDA Grants Bionomics Fast Track Designation to BNC210 for the Acute Treatment of Social Anxiety Disorder and Other Anxiety Related DisordersBionomics Limited (ASX:BNO, OTCQB:BNOEF) ( Bionomics or Company), a clinical-stage biopharmaceutical company, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the BNC210 developmentRHEA-AIvery positive
11/23/21 6:37 AMOTC : BNOEF, BNOEF.OB IPOofferingBionomics Files Registration Statement for Proposed Initial Public Offering in the United StatesBionomics Limited (ASX:BNO, OTCQB:BNOEF) ( Bionomics or Company), a clinical-stage biopharmaceutical company, today announced the public filing of a registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the "SEC") inRHEA-AIneutral
11/01/21 6:00 AMOTC : BNOEF, BNOEF.OB clinical trialBionomics Receives FDA Clearance of IND for Evaluation of BNC210 in a Phase 2 Social Anxiety Disorder PREVAIL StudyU.S. FDA clearance of IND for BNC210 evaluation as an acute treatment for patients with Social Anxiety Disorder in a Phase 2 clinical trial, the PREVAIL Study The PREVAIL Study remains on target to initiate by end of 2021 and is expected to read out topline data by end of 2022 ADELAIDE, Australia,RHEA-AIneutral
04/09/21 6:00 AMOTC : BNOEF, BNOEF.OB Bionomics Successfully Completes A$22.9 million Equity RaiseBionomics Limited (ASX: BNO, OTCQB:BNOEF) ( Bionomics) has completed its 1 for 6 pro rata non–renounceable entitlement offer that was announced on 8 March 2021 ( Entitlement Offer) and concurrent placement that was announced on 17 March 2021 (RHEA-AIneutral
02/22/21 6:00 AMOTC : BNOEF, BNOEF.OB clinical trialPositive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood Exposure Projected for Phase 2b PTSD TrialBionomics Limited (ASX: BNO,RHEA-AIpositive
02/17/21 6:00 AMOTC : BNOEF, BNOEF.OB Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment regimen for PTSDBionomics Limited (ASX: BNO, OTCQB: BNOEF, Germany : AU000000BNO5) ( Bionomics) today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc ( EmpathBio), a wholly owned subsidiary of Germany -based CNS clinicalRHEA-AIvery positive
02/10/21 6:00 AMOTC : BNOEF, BNOEF.OB $16 Million Capital Raise to Progress Bionomics BNC210 PTSD TrialCommitments received for a placement of A$15,991,634 at A$0.145 per share Significant participation from North American and European institutional and sophisticated investors This capital raising enables proceeding with the Phase 2b PTSD trial in mid-2021 as planned and sees the Company wellRHEA-AIvery positive
